Trxade Health, Inc (MEDS) SEC Filing 8-K Material Event for the period ending Wednesday, February 9, 2022

Trxade Group, Inc.

CIK: 1382574 Ticker: MEDS

View differences made from one to another to evaluate Trxade Group, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Trxade Group, Inc..


Assess how Trxade Group, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Trxade Group, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Trxade Group, Inc. provided additional information to their SEC Filing as exhibits

Ticker: MEDS
CIK: 1382574
Form Type: 8-K Corporate News
Accession Number: 0001493152-22-003615
Submitted to the SEC: Wed Feb 09 2022 4:35:14 PM EST
Accepted by the SEC: Wed Feb 09 2022
Period: Wednesday, February 9, 2022
Industry: Wholesale Drugs Proprietaries And Druggists Sundries
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: